PriceTargets.com logo

Oculis - OCS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.20
  • Forecasted Upside: 67.34%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$17.45 As of 12/17/2024 01:00 AM ET
▲ +0.35 (2.05%)

This chart shows the closing price for OCS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oculis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCS

Analyst Price Target is $29.20
▲ +67.34% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Oculis in the last 3 months. The average price target is $29.20, with a high forecast of $37.00 and a low forecast of $20.00. The average price target represents a 67.34% upside from the last price of $17.45.

This chart shows the closing price for OCS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Oculis.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
6/11/2024Chardan CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
6/11/2024HC WainwrightBoost TargetBuy ➝ Buy$28.00 ➝ $30.00
6/11/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$35.00 ➝ $37.00
6/11/2024Bank of AmericaLower TargetBuy ➝ Buy$21.00 ➝ $20.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/24/2024HC WainwrightLower TargetBuy ➝ Buy$29.00 ➝ $28.00
3/19/2024Chardan CapitalReiterated RatingBuy ➝ Buy$30.00
3/19/2024Robert W. BairdLower TargetOutperform ➝ Outperform$64.00 ➝ $35.00
3/6/2024WedbushReiterated RatingOutperform ➝ Outperform$29.00
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$29.00
12/5/2023Chardan CapitalInitiated CoverageBuy$30.00
11/17/2023WedbushReiterated RatingOutperform ➝ Outperform$29.00
10/4/2023Stifel NicolausInitiated CoverageBuy$35.00
8/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$29.00
8/29/2023Bank of AmericaBoost TargetBuy ➝ Buy$23.00 ➝ $24.00
8/9/2023Robert W. BairdBoost Target$58.00 ➝ $64.00
8/9/2023HC WainwrightBoost Target$28.00 ➝ $29.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
6/14/2023Bank of AmericaInitiated CoverageBuy$22.00
6/12/2023Leerink PartnersReiterated RatingOutperform
6/12/2023SVB SecuritiesInitiated CoverageOutperform
6/12/2023HC WainwrightInitiated CoverageBuy$28.00
6/7/2023Robert W. BairdInitiated CoverageOutperform
5/10/2023Pareto SecuritiesInitiated CoverageBuy$23.00
4/28/2023WedbushInitiated CoverageOutperform$27.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 7 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Oculis logo
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Read More

Today's Range

Now: $17.45
Low: $17.16
High: $17.49

50 Day Range

MA: $15.78
Low: $14.03
High: $17.88

52 Week Range

Now: $17.45
Low: $9.60
High: $18.00

Volume

56,368 shs

Average Volume

37,236 shs

Market Capitalization

$706.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Oculis?

The following equities research analysts have issued reports on Oculis in the last twelve months: Bank of America Co., Chardan Capital, HC Wainwright, Robert W. Baird, and Wedbush.
View the latest analyst ratings for OCS.

What is the current price target for Oculis?

0 Wall Street analysts have set twelve-month price targets for Oculis in the last year. Their average twelve-month price target is $29.20, suggesting a possible upside of 67.3%. Robert W. Baird has the highest price target set, predicting OCS will reach $37.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $20.00 for Oculis in the next year.
View the latest price targets for OCS.

What is the current consensus analyst rating for Oculis?

Oculis currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCS will outperform the market and that investors should add to their positions of Oculis.
View the latest ratings for OCS.

What other companies compete with Oculis?

Other companies that are similar to Oculis include Bausch Health Companies, Arrowhead Pharmaceuticals, Dyne Therapeutics, HUTCHMED and Catalyst Pharmaceuticals. Learn More about companies similar to Oculis.

How do I contact Oculis' investor relations team?

The company's listed phone number is 41-21-711-3970 and its investor relations email address is [email protected]. The official website for Oculis is www.oculis.com. Learn More about contacing Oculis investor relations.